Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

279.84 +1.94 (+0.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Eli Lilly and Viking Therapeutics jumped on Novo's setback. 
Via Investor's Business Daily
10 Biggest Losers of The Dow Jones Index's 10-Day Losing Streak
Investors shrugged off the meltdown on Thursday. A few Dow laggards rebounded. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked. 
Via Investor's Business Daily
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
Unpacking the Latest Options Trading Trends in Amgen
Via Benzinga
Demystifying Amgen: Insights From 13 Analyst Reviews
Via Benzinga
Is Amgen Still a Top Dividend Stock?
Via The Motley Fool
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
Via The Motley Fool
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?
Via The Motley Fool
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Via The Motley Fool
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Looking for reliable income in the stock market? You might want to consider the top Dogs of the Dow in December. Here's what you need to know about this trio of blue-chip stocks. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
MarketBeat Week in Review – 12/2 - 12/6
Equities continued their post-election rally after Friday’s solid November jobs report and all signs point to the rally in stocks extending into 2025 
Via MarketBeat
Topics Economy Government Immigration
Exposures Economy Immigration Interest Rates
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies. 
Via MarketBeat
13 Healthcare Sector Stocks With Healthy Valuation
We are looking for value in the Healthcare Sector because we are still in a strong bull market that has been not only one of the longest on record, but also has seen the S&P 500 get to one of its lofty... 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable. 
Via The Motley Fool
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
Via The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
Via The Motley Fool
Stock Market Hits Highs Despite Trump Tariff Threats, Nvidia, Tech Turkeys: Weekly Review
The Nasdaq isn't at a high, but it isn't far off either. 
Via Investor's Business Daily
Topics Government
Exposures Political
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?
Via The Motley Fool
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
Exposures Intellectual Property Political Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
The U.S. stock market traded mixed on Tuesday morning, with major indices showing tight movements as investors awaited the release of the Federal Reserve's November meeting minutes. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.